Natalie Hoog-Labouret

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

Denis Moro‐Sibilot, Nathalie Cozic, M. Pérol et al. · Annals of Oncology · 2019 · 194 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report

Morgane Broudic-Guibert, Jean‐Yves Blay, Léa Vazquez et al. · Journal of Medical Case Reports · 2019 · 60 citations · Full text

Medicine, Oncology, Pharmacology +15

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i> -Mutant Metastatic Non–Small Cell Lung Cancer

Sandra Ortiz‐Cuaran, Laura Mezquita, Aurélie Swalduz et al. · Clinical Cancer Research · 2020 · 46 citations · Full text

Medicine, Molecular Genetics, Oncology +17

526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours

Benoı̂t Rousseau, Ivan Bièche, Éric Pasmant et al. · Annals of Oncology · 2020 · 29 citations

Life Sciences, Molecular Biology, Oncology +15

1619O High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study

Jean‐Yves Blay, Sylvie Chevret, Nicolas Penel et al. · Annals of Oncology · 2020 · 14 citations

Medicine, Oncology, Pharmacology +13